Press Release

Sep, 06 2023

Empowering Healthcare at Fingertips: Impact of Point of Care Testing (POCT)

Point of Care Testing (POCT) revolutionizes healthcare delivery by enabling rapid diagnostics at the patient's location. Its applications span various medical settings, including clinics, hospitals, and remote areas. POCT devices offer user-friendly interfaces, yielding quick and accurate results for conditions such as diabetes, cardiac markers, and infectious disease. These features enhance patient care by facilitating immediate treatment decisions, reducing turnaround times, and extending healthcare access to underserved regions, ultimately optimizing medical outcomes.

Access Full Report @

Data Bridge Market Research analyses that the Europe Point-Of-Care-Testing (POCT) Market is valued at USD 6,664.28 million in 2021 and is expected to reach USD 13,085.33 million by 2029, registering a CAGR of 8.8% during the forecast period of 2022 to 2029. Point of care testing (POCT) provides rapid diagnostic results directly at the patient's location, enabling healthcare professionals to make immediate treatment decisions. This swift access to critical information enhances patient care by minimizing delays in diagnosis and intervention, leading to more timely and effective medical management.

Key Findings of the Study

Europe Point-Of-Care-Testing (POCT) Market

Early diagnosis and intervention are expected to drive the market's growth rate

Point of care testing (POCT) plays a pivotal role in the early identification of diseases, enabling swift initiation of treatments and ultimately leading to better patient results. Providing rapid and on-the-spot diagnostic information, healthcare professionals can promptly intervene with appropriate therapies, preventing disease progression and complications. This proactive approach significantly improves the effectiveness of medical interventions, enhances patient prognosis, and contributes to overall healthcare system efficiency.

Report Scope and Market Segmentation

Report Metric


Forecast Period

2022 to 2029

Base Year


Historic Years

2020 (Customizable to 2014-2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Products (Instruments, Consumables and Reagents and Others), Application (Blood Glucose, Cardiac Monitoring, Coagulation, Whole Blood Analysis, Vital Sign Monitoring, Infectious Disease Testing, Urine Analysis, Cholesterol Testing and Others), End User (Laboratories, Hospitals, Clinics, Ambulatory Centers, Homecare, Assisted Living Facilities, Pharmacies/Drug Stores and Others), Mode of Testing (Prescription-Based Testing and OTC Testing), Distribution Channel (Direct Sales, Third Party Distributor and Online Sale)

Countries Covered

Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe

Market Players Covered

Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Quidel Corporation (U.S.), Trividia Health, Inc. (U.S.), Nova Biomedical (U.S.), PTS Diagnostics (U.S.), Trinity Biotech (Ireland), LumiraDx (U.K.), Sekisui Diagnostics (U.S.), Chembio Diagnostics, Inc. (U.S.), BD (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), Danaher (U.S.), binx health, inc (U.S.), QuantuMDx Group Ltd. (U.K.), Werfen (Spain), Abaxis (U.S.), EKF Diagnostics (U.K.), Sysmex Europe SE (Germany)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework

Segment Analysis:

The Europe point-of-care-testing (POCT) market is segmented on the basis of product, application, end user, mode of testing, and distribution channel.

  • On the basis of product, the market is segmented into instruments, consumables and reagents, and others.
  • On the basis of application, the market is segmented into blood glucose, cardiac monitoring, coagulation, whole blood analysis, vital sign monitoring, infectious disease testing, urine analysis, cholesterol testing, and others.
  • On the basis of end user, the market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, pharmacies/drug stores, and others.
  • On the basis of mode of testing, the market is segmented into prescription-based testing and OTC testing.
  • On the basis of distribution channel, the market is segmented into direct sales, third party distributor, and online sale.

Major Players

Data Bridge Market Research recognizes the following companies as the major Europe point-of-care-testing (POCT) market players in Europe point-of-care-testing (POCT) market Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Quidel Corporation (U.S.), Trividia Health, Inc. (U.S.), Nova Biomedical (U.S.), PTS Diagnostics (U.S.), Trinity Biotech (Ireland), LumiraDx (U.K.),

Europe Point-Of-Care-Testing (POCT) Market

Market Developments

  • In May 2022, Abbott has enhanced the i-STAT software, offering real-time solutions for hospitals and outpatient facilities. This updated software boasts a high efficacy rate, cost-effectiveness, and supports quality patient care decision-making, ensuring efficient and accurate healthcare solutions.
  • In May 2022, EKF Diagnostics introduced the EKF Link digital connectivity solution, designed for the secure centralized management of Point of Care (POC) analyzers and their associated data. This platform streamlines the management process, ensuring data security and enhancing the efficiency of POC testing operations.
  • In May 2022, QuantuMDx has introduced its latest respiratory panel test, the Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay, to the market.
  • In March 2022, With the goal of extending its line of biomarker-based rapid testing products across North America, Boditech Med has formed a strategic partnership with Novo Integrated Sciences, Inc.
  • In January 2022, Roche has introduced its Cobas Pulse System in certain countries that acknowledge the CE Mark. This advanced offering from Roche Diagnostics represents their latest connected point-of-care solution designed for professional blood glucose management.

Regional Analysis

Geographically, the countries covered in the Europe point-of-care-testing (POCT) market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

As per Data Bridge Market Research analysis:

Germany is the dominant region in Europe point-of-care-testing (POCT) market during the forecast period 2022 - 2029

In 2022, Germany dominated the point-of-care-testing (POCT) market due to growing awareness encompasses the benefits of on-site testing, offering quick results that enhance patient care, expedite treatment choices, and elevate disease management. This increased familiarity with POCT's capabilities propels its adoption as a fundamental element of contemporary healthcare practices throughout Europe.

For more detailed information about the point-of-care-testing (POCT) market report, click here –

Client Testimonials